by Tang Shihua for Yicai Global

“(Yicai) Sept. 1 — Huadong Medicine, one of China’s most diversified makers of dermatosis medicines, will purchase exclusive rights for a first-in-class skin disease treatment developed by UK firm MC2 Therapeutics in China.

Huadong’s unit Hangzhou Zhongmei Huadong Pharmaceutical will pay USD16 million down payment and up to USD36 million milestone payment for the clinical development, new drug registration, and commercialization exclusive rights and interests of Wynzora Cream in the Chinese mainland, Hong Kong, Macao, and Taiwan, the Hangzhou-based drugmaker announced yesterday.

After Wynzora hits the market, MC2 Therapeutics will receive a commission payment equal to a double-digit percentage of the drug’s net sales amount, Huadong noted…”

Continue reading at the original source, linked here.